Merck & Co., Inc. (MRK) Advances Oncology Pipeline with Breakthrough FDA Designation for Ovarian Cancer Drug

We recently compiled a list of the 12 Most Undervalued Dow Stocks to Buy According to Analysts. Merck & Co., Inc. is one of them.

Merck & Co., Inc. (NYSE:MRK) tops our list for being one of the most undervalued stocks. It is a global healthcare leader in pharmaceuticals, vaccines, biologics, and animal health products.

A major recent development is the FDA approval of KEYTRUDA QLEX, a new subcutaneous injectable formulation of the company’s blockbuster cancer therapy Keytruda, on September 19, 2025. This injection can be administered in one to two minutes, compared with the traditional 30-minute intravenous infusion, enhancing patient convenience and clinical efficiency. The U.S. rollout is expected by late September, with projections suggesting it could capture 30-40% of Keytruda users within two years, helping MRK maintain market leadership amid biosimilar competition.

In Europe, Merck & Co., Inc. (NYSE:MRK) received a positive opinion from the European Medicines Agency for ENFLONSIA (clesrovimab), an RSV preventive for infants during their first RSV season. If approved, it will be the first weight-independent RSV preventive option for European infants, addressing a significant unmet need.

Financially, Merck & Co., Inc. (NYSE:MRK) reported strong Q2 2025 results. Analysts continue to highlight its robust vaccine franchise, animal health segment, and innovative oncology treatments, including combination therapies with Keytruda. The corporation is also advancing novel drug candidates, such as raludotatug deruxtecan, which recently received FDA Breakthrough Therapy Designation for platinum-resistant ovarian and related cancers, accelerating development for patients with high unmet medical needs.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.